{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T16:03:51Z","timestamp":1794326631300,"version":"4.9.0"},"reference-count":85,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T00:00:00Z","timestamp":1749081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T00:00:00Z","timestamp":1749081600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1007\/s12325-025-03257-w","type":"journal-article","created":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T11:09:15Z","timestamp":1749121755000},"page":"3621-3633","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["GLP-1 Receptor Agonists, DPP-4 Inhibitors and the Skin\u2014Diabetes Meets Dermatology: A Brief Narrative Review"],"prefix":"10.1007","volume":"42","author":[{"given":"Dimitrios","family":"Pantazopoulos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evanthia","family":"Gouveri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Papi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios","family":"Papazoglou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7320-785X","authenticated-orcid":false,"given":"Nikolaos","family":"Papanas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,5]]},"reference":[{"key":"3257_CR1","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1016\/j.tips.2009.08.003","volume":"30","author":"R Yazbeck","year":"2009","unstructured":"Yazbeck R, Howarth GS, Abbott CA. Dipeptidyl peptidase inhibitors, an emerging drug class for inflammatory disease? Trends Pharmacol Sci. 2009;30:600\u20137.","journal-title":"Trends Pharmacol Sci"},{"key":"3257_CR2","doi-asserted-by":"crossref","unstructured":"Davies MJ, Aroda VR, Collins BS, et al. Management of hyperglycaemia in type\u00a02 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) Diabetologia. 2022;65:1925\u201366.","DOI":"10.1007\/s00125-022-05787-2"},{"key":"3257_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2020.101102","volume":"46","author":"MA Nauck","year":"2021","unstructured":"Nauck MA, Quast DR, Wefers J, Meier JJ. GLP-1 receptor agonists in the treatment of type\u00a02 diabetes\u2014state-of-the-art. Mol Metab. 2021;46:101102.","journal-title":"Mol Metab"},{"key":"3257_CR4","first-page":"509","volume":"35","author":"R Pathak","year":"2010","unstructured":"Pathak R, Bridgeman MB. Dipeptidyl peptidase-4 (DPP-4) inhibitors in the management of diabetes. P T. 2010;35:509\u201313.","journal-title":"P T"},{"key":"3257_CR5","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1517\/14740338.2015.977863","volume":"14","author":"SH Tella","year":"2015","unstructured":"Tella SH, Rendell MS. DPP-4 inhibitors: focus on safety. Expert Opin Drug Saf. 2015;14:127\u201340.","journal-title":"Expert Opin Drug Saf"},{"key":"3257_CR6","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1038\/nrendo.2012.140","volume":"8","author":"JJ Meier","year":"2012","unstructured":"Meier JJ. GLP-1 receptor agonists for individualized treatment of type\u00a02 diabetes mellitus. Nat Rev Endocrinol. 2012;8:728\u201342.","journal-title":"Nat Rev Endocrinol"},{"key":"3257_CR7","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1038\/s42255-020-00327-x","volume":"3","author":"FM Gribble","year":"2021","unstructured":"Gribble FM, Reimann F. Metabolic messengers: glucagon-like peptide 1. Nat Metab. 2021;3:142\u20138.","journal-title":"Nat Metab"},{"key":"3257_CR8","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1055\/s-2004-826178","volume":"36","author":"B Ahren","year":"2004","unstructured":"Ahren B, Schmitz O. GLP-1 receptor agonists and DPP-4 inhibitors in the treatment of type\u00a02 diabetes. Horm Metab Res. 2004;36:867\u201376.","journal-title":"Horm Metab Res"},{"key":"3257_CR9","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1007\/s00125-010-1896-4","volume":"54","author":"MA Nauck","year":"2011","unstructured":"Nauck MA, Verdari I, Deacon CF, et al. Secretion of glucagon-like peptide-1 (GLP-1) in type\u00a02 diabetes: what is up, what is down? Diabetologia. 2011;54:10\u20138.","journal-title":"Diabetologia"},{"key":"3257_CR10","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1111\/dom.12596","volume":"18","author":"S Madsbad","year":"2016","unstructured":"Madsbad S. Review of head-to-head comparisons of glucagon-like peptide-1 receptor agonists. Diabetes Obes Metab. 2016;18:317\u201332.","journal-title":"Diabetes Obes Metab"},{"issue":"Suppl 1","key":"3257_CR11","doi-asserted-by":"publisher","first-page":"S181","DOI":"10.2337\/dc25-S009","volume":"48","author":"American Diabetes Association Professional Practice Committee","year":"2025","unstructured":"American Diabetes Association Professional Practice Committee. Pharmacologic approaches to glycemic treatment: standards of care in diabetes\u20142025. Diabetes Care. 2025;48(Suppl 1):S181\u2013206.","journal-title":"Diabetes Care"},{"key":"3257_CR12","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s13300-023-01506-1","volume":"15","author":"E Gouveri","year":"2024","unstructured":"Gouveri E, Popovic DS, Papanas N. Potential new therapeutic implications of semaglutide: new colours of the rainbow? Diabetes Ther. 2024;15:13\u20138.","journal-title":"Diabetes Ther"},{"key":"3257_CR13","doi-asserted-by":"publisher","first-page":"1148209","DOI":"10.3389\/fimmu.2023.1148209","volume":"14","author":"SF Mehdi","year":"2023","unstructured":"Mehdi SF, Pusapati S, Anwar MS, et al. Glucagon-like peptide-1: a multi-faceted anti-inflammatory agent. Front Immunol. 2023;14:1148209.","journal-title":"Front Immunol"},{"key":"3257_CR14","doi-asserted-by":"publisher","first-page":"433","DOI":"10.2147\/DMSO.S193693","volume":"13","author":"RA Chudleigh","year":"2020","unstructured":"Chudleigh RA, Platts J, Bain SC. Comparative effectiveness of long-acting GLP-1 receptor agonists in type\u00a02 diabetes: a short review on the emerging data. Diabetes Metab Syndr Obes. 2020;13:433\u20138.","journal-title":"Diabetes Metab Syndr Obes"},{"key":"3257_CR15","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1038\/d41573-019-00177-7","volume":"18","author":"L Urquhart","year":"2019","unstructured":"Urquhart L. FDA new drug approvals in Q3 2019. Nat Rev Drug Discov. 2019;18:816.","journal-title":"Nat Rev Drug Discov"},{"key":"3257_CR16","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.vph.2011.05.001","volume":"55","author":"GP Fadini","year":"2011","unstructured":"Fadini GP, Avogaro A. Cardiovascular effects of DPP-4 inhibition: beyond GLP-1. Vascul Pharmacol. 2011;55:10\u20136.","journal-title":"Vascul Pharmacol"},{"key":"3257_CR17","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1517\/13543784.17.6.845","volume":"17","author":"N Mikhail","year":"2008","unstructured":"Mikhail N. Incretin mimetics and dipeptidyl peptidase inhibitors in clinical trials for the treatment of type\u00a02 diabetes. Expert Opin Investig Drugs. 2008;17:845\u201353.","journal-title":"Expert Opin Investig Drugs"},{"key":"3257_CR18","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.bcp.2009.03.032","volume":"78","author":"JJ Wu","year":"2009","unstructured":"Wu JJ, Tang HK, Yeh TK, et al. Biochemistry, pharmacokinetics, and toxicology of a potent and selective DPP8\/9 inhibitor. Biochem Pharmacol. 2009;78:203\u201310.","journal-title":"Biochem Pharmacol"},{"key":"3257_CR19","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/978-1-4757-9613-1_15","volume":"421","author":"M Hegen","year":"1997","unstructured":"Hegen M, Kameoka J, Dong RP, Morimoto C, Schlossman SF. Structure of CD26 (dipeptidyl peptidase\u00a0IV) and function in human T\u00a0cell activation. Adv Exp Med Biol. 1997;421:109\u201316.","journal-title":"Adv Exp Med Biol"},{"key":"3257_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/cei.12781","volume":"185","author":"C Klemann","year":"2016","unstructured":"Klemann C, Wagner L, Stephan M, von H\u00f6rsten S. Cut to the chase: a review of CD26\/dipeptidyl peptidase-4\u2019s (DPP4) entanglement in the immune system. Clin Exp Immunol. 2016;185:1\u201321.","journal-title":"Clin Exp Immunol"},{"key":"3257_CR21","unstructured":"Kasina SVSK, Baradhi KM. Dipeptidyl peptidase\u00a0IV (DPP IV) inhibitors. [Updated 2023 May\u00a022]. Treasure Island (FL): StatPearls; 2025. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK542331\/#. Accessed 29 Apr 2025."},{"key":"3257_CR22","first-page":"34","volume":"17","author":"K Lal","year":"2024","unstructured":"Lal K, Herringshaw E. The use of GLP-1 agonists in the management of cutaneous disease. J Clin Aesthet Dermatol. 2024;17:34\u20137.","journal-title":"J Clin Aesthet Dermatol"},{"key":"3257_CR23","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1007\/s00403-024-02969-3","volume":"316","author":"CE Salazar","year":"2024","unstructured":"Salazar CE, Patil MK, Aihie O, Cruz N, Nambudiri VE. Rare cutaneous adverse reactions associated with GLP-1 agonists: a review of the published literature. Arch Dermatol Res. 2024;316:248.","journal-title":"Arch Dermatol Res"},{"key":"3257_CR24","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/S2213-8587(17)30085-2","volume":"5","author":"VR Aroda","year":"2017","unstructured":"Aroda VR, Bain SC, Cariou B, et al. Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type\u00a02 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase\u00a03a trial. Lancet Diabetes Endocrinol. 2017;5:355\u201366.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"3257_CR25","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.1029","volume":"10","author":"L Jones","year":"2022","unstructured":"Jones L, Jones AM. Suspected adverse drug reactions of the type\u00a02 antidiabetic drug class dipeptidyl-peptidase\u00a0IV inhibitors (DPP4i): can polypharmacology help explain? Pharmacol Res Perspect. 2022;10:e01029.","journal-title":"Pharmacol Res Perspect"},{"key":"3257_CR26","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1111\/j.1346-8138.2011.01372.x","volume":"39","author":"K Tanaka","year":"2012","unstructured":"Tanaka K, Ogawa Y, Shimada S. Drug eruption caused by sitagliptin, a dipeptidyl peptidase-IV inhibitor. J Dermatol. 2012;39:726\u20138.","journal-title":"J Dermatol"},{"key":"3257_CR27","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s40360-020-00447-w","volume":"21","author":"J Huang","year":"2020","unstructured":"Huang J, Jia Y, Sun S, Meng L. Adverse event profiles of dipeptidyl peptidase-4 inhibitors: data mining of the public version of the FDA adverse event reporting system. BMC Pharmacol Toxicol. 2020;21:68.","journal-title":"BMC Pharmacol Toxicol"},{"key":"3257_CR28","doi-asserted-by":"publisher","first-page":"304","DOI":"10.2174\/157488611798918700","volume":"6","author":"N Mikhail","year":"2011","unstructured":"Mikhail N. Safety of dipeptidyl peptidase 4 inhibitors for treatment of type\u00a02 diabetes. Curr Drug Saf. 2011;6:304\u20139.","journal-title":"Curr Drug Saf"},{"key":"3257_CR29","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1111\/j.1463-1326.2010.01214.x","volume":"12","author":"M Ligueros-Saylan","year":"2010","unstructured":"Ligueros-Saylan M, Foley JE, Schweizer A, Couturier A, Kothny W. An assessment of adverse effects of vildagliptin versus comparators on the liver, the pancreas, the immune system, the skin and in patients with impaired renal function from a large pooled database of phase\u00a0II and III clinical trials. Diabetes Obes Metab. 2010;12:495\u2013509.","journal-title":"Diabetes Obes Metab"},{"key":"3257_CR30","unstructured":"European Medicines Agency. Galvus (vildagliptin)\u2014European Public Assessment Report (EPAR)\u2014scientific discussion. 2007. http:\/\/www.emea.europa.eu\/humandocs\/PDFs\/EPAR\/galvus\/H771-en6.pdf. Accessed 8 Mar 2025."},{"key":"3257_CR31","doi-asserted-by":"crossref","unstructured":"Psomadakis C, Shahzad N, Katz J. Linagliptin-associated blistering and ulceration. BMJ Case Rep. 2017;2017:bcr2017219998.","DOI":"10.1136\/bcr-2017-219998"},{"key":"3257_CR32","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1001\/archinternmed.2010.188","volume":"170","author":"S Desai","year":"2010","unstructured":"Desai S, Brinker A, Swann J, et al. Sitagliptin-associated drug allergy: review of spontaneous adverse event reports. Arch Intern Med. 2010;170:1169\u201371.","journal-title":"Arch Intern Med"},{"key":"3257_CR33","unstructured":"Januvia (sitagliptin). Prescribing Information. Merck& Co., Inc., Whitehouse Station, NJ 08889, USA 2011."},{"key":"3257_CR34","doi-asserted-by":"publisher","first-page":"711","DOI":"10.3390\/ijms19030711","volume":"19","author":"HJ Lee","year":"2018","unstructured":"Lee HJ, Jang YJ. Recent understandings of biology, prophylaxis and treatment strategies for hypertrophic scars and keloids. Int J Mol Sci. 2018;19:711.","journal-title":"Int J Mol Sci"},{"key":"3257_CR35","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/j.ejphar.2018.10.053","volume":"842","author":"M Wolak","year":"2019","unstructured":"Wolak M, Staszewska T, Juszczak M, Ga\u0142dyszy\u0144ska M, Bojanowska E. Anti-inflammatory and pro-healing impacts of exendin-4 treatment in zucker diabetic rats: effects on skin wound fibroblasts. Eur J Pharmacol. 2019;842:262\u20139.","journal-title":"Eur J Pharmacol"},{"key":"3257_CR36","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.diabres.2018.10.013","volume":"146","author":"K Nagae","year":"2018","unstructured":"Nagae K, Uchi H, Morino-Koga S, et al. Glucagon-like peptide-1 analogue liraglutide facilitates wound healing by activating PI3K\/Akt pathway in keratinocytes. Diabetes Res Clin Pract. 2018;146:155\u201361.","journal-title":"Diabetes Res Clin Pract"},{"key":"3257_CR37","doi-asserted-by":"publisher","first-page":"6242","DOI":"10.1038\/s41467-021-26495-2","volume":"12","author":"V Vorstandlechner","year":"2021","unstructured":"Vorstandlechner V, Laggner M, Copic D, et al. The serine proteases dipeptidyl-peptidase 4 and urokinase are key molecules in human and mouse scar formation. Nat Commun. 2021;12:6242.","journal-title":"Nat Commun"},{"key":"3257_CR38","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1111\/exd.13751","volume":"27","author":"CM Shih","year":"2018","unstructured":"Shih CM, Huang CY, Huang CY, et al. A dipeptidyl peptidase-4 inhibitor promotes wound healing in normoglycemic mice by modulating keratinocyte activity. Exp Dermatol. 2018;27:1134\u201341.","journal-title":"Exp Dermatol"},{"key":"3257_CR39","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.2174\/1389557520666200628032507","volume":"20","author":"ZG Sun","year":"2020","unstructured":"Sun ZG, Li ZN, Zhu HL. The research progress of DPP-4 inhibitors. Mini Rev Med Chem. 2020;20:1709\u201318.","journal-title":"Mini Rev Med Chem"},{"key":"3257_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2022.113143","volume":"151","author":"KW Zhang","year":"2022","unstructured":"Zhang KW, Liu SY, Jia Y, et al. Insight into the role of DPP-4 in fibrotic wound healing. Biomed Pharmacother. 2022;151: 113143.","journal-title":"Biomed Pharmacother"},{"key":"3257_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2023.110364","volume":"120","author":"Z Meng","year":"2023","unstructured":"Meng Z, Wang K, Lan Q, et al. Saxagliptin promotes random skin flap survival. Int Immunopharmacol. 2023;120:110364.","journal-title":"Int Immunopharmacol"},{"key":"3257_CR42","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1111\/j.1468-3083.2011.04062.x","volume":"26","author":"K Skandalis","year":"2012","unstructured":"Skandalis K, Spirova M, Gaitanis G, Tsartsarakis A, Bassukas ID. Drug-induced bullous pemphigoid in diabetes mellitus patients receiving dipeptidyl peptidase-IV inhibitors plus metformin. J Eur Acad Dermatol Venereol. 2012;26:249\u201353.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"3257_CR43","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1001\/jamadermatol.2013.1073","volume":"149","author":"I Aouidad","year":"2013","unstructured":"Aouidad I, Fite C, Marinho E, et al. A case report of bullous pemphigoid induced by dipeptidyl peptidase-4 inhibitors. JAMA Dermatol. 2013;149:243\u20135.","journal-title":"JAMA Dermatol"},{"key":"3257_CR44","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1111\/jdi.12695","volume":"9","author":"S Yoshiji","year":"2018","unstructured":"Yoshiji S, Murakami T, Harashima SI, et al. Bullous pemphigoid associated with dipeptidyl peptidase-4 inhibitors: a report of five cases. J Diabetes Investig. 2018;9:445\u20137.","journal-title":"J Diabetes Investig"},{"key":"3257_CR45","doi-asserted-by":"publisher","first-page":"24","DOI":"10.3315\/jdcr.2014.1166","volume":"8","author":"A Attaway","year":"2014","unstructured":"Attaway A, Mersfelder TL, Vaishnav S, Baker JK. Bullous pemphigoid associated with dipeptidyl peptidase\u00a0IV inhibitors. A case report and review of literature. J Dermatol Case Rep. 2014;8:24\u20138.","journal-title":"J Dermatol Case Rep"},{"key":"3257_CR46","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s12016-007-0030-y","volume":"33","author":"M Kasperkiewicz","year":"2007","unstructured":"Kasperkiewicz M, Zillikens D. The pathophysiology of bullous pemphigoid. Clin Rev Allergy Immunol. 2007;33:67\u201377.","journal-title":"Clin Rev Allergy Immunol"},{"key":"3257_CR47","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1038\/jid.2010.301","volume":"131","author":"S Bastuji-Garin","year":"2011","unstructured":"Bastuji-Garin S, Joly P, Lemordant P, et al. Risk factors for bullous pemphigoid in the elderly: a prospective case-control study. J Investig Dermatol. 2011;131:637\u201343.","journal-title":"J Investig Dermatol"},{"key":"3257_CR48","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.3391","volume":"37","author":"W Yang","year":"2021","unstructured":"Yang W, Cai X, Zhang S, Han X, Ji L. Dipeptidyl peptidase-4 inhibitor treatment and the risk of bullous pemphigoid and skin-related adverse events: a systematic review and meta-analysis of randomized controlled trials. Diabetes Metab Res Rev. 2021;37:e3391.","journal-title":"Diabetes Metab Res Rev"},{"key":"3257_CR49","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/j.jaad.2018.09.048","volume":"85","author":"K Kridin","year":"2021","unstructured":"Kridin K, Cohen AD. Dipeptidyl-peptidase\u00a0IV inhibitor-associated bullous pemphigoid: a systematic review and meta-analysis. J Am Acad Dermatol. 2021;85:501\u20133.","journal-title":"J Am Acad Dermatol"},{"key":"3257_CR50","doi-asserted-by":"publisher","first-page":"e879","DOI":"10.1111\/jdv.18975","volume":"37","author":"H Kang","year":"2023","unstructured":"Kang H, Lee EB, Lee S, et al. Dipeptidyl peptidase-4 inhibitors increase the risk of bullous pemphigoid in older patients with diabetes: a retrospective analysis using the Korean National Health Insurance Database. J Eur Acad Dermatol Venereol. 2023;37:e879\u201381.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"3257_CR51","doi-asserted-by":"publisher","first-page":"e15","DOI":"10.1111\/ajd.13100","volume":"61","author":"K Phan","year":"2020","unstructured":"Phan K, Charlton O, Smith SD. Dipeptidyl peptidase-4 inhibitors and bullous pemphigoid: a systematic review and adjusted meta-analysis. Australas J Dermatol. 2020;61:e15\u201321.","journal-title":"Australas J Dermatol"},{"key":"3257_CR52","doi-asserted-by":"publisher","first-page":"2201","DOI":"10.1016\/j.jid.2016.06.622","volume":"136","author":"K Izumi","year":"2016","unstructured":"Izumi K, Nishie W, Mai Y, et al. Autoantibody profile differentiates between inflammatory and noninflammatory bullous pemphigoid. J Investig Dermatol. 2016;136:2201\u201310.","journal-title":"J Investig Dermatol"},{"key":"3257_CR53","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdiacomp.2019.107515","volume":"34","author":"JY Guo","year":"2020","unstructured":"Guo JY, Chen HH, Yang YC, Wu PY, Chang MP, Chen CC. The association of dipeptidyl peptidase\u00a0IV inhibitors and other risk factors with bullous pemphigoid in patients with type\u00a02 diabetes mellitus: a retrospective cohort study. J Diabetes Complic. 2020;34:107515.","journal-title":"J Diabetes Complic"},{"key":"3257_CR54","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.4049\/jimmunol.181.2.1120","volume":"181","author":"U Forssmann","year":"2008","unstructured":"Forssmann U, Stoetzer C, Stephan M, et al. Inhibition of CD26\/ dipeptidyl peptidase\u00a0IV enhances CCL11\/eotaxin-mediated recruitment of eosinophils in vivo. J Immunol. 2008;181:1120\u20137.","journal-title":"J Immunol"},{"key":"3257_CR55","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s40842-024-00165-w","volume":"10","author":"S Zaresharifi","year":"2024","unstructured":"Zaresharifi S, Niroomand M, Borran S, Dadkhahfar S. Dermatological side effects of dipeptidyl peptidase-4 inhibitors in diabetes management: a comprehensive review. Clin Diabetes Endocrinol. 2024;10:6.","journal-title":"Clin Diabetes Endocrinol"},{"key":"3257_CR56","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.3389\/fimmu.2018.01030","volume":"9","author":"O Gaudin","year":"2018","unstructured":"Gaudin O, Seta V, Alexandre M, et al. Gliptin accountability in mucous membrane pemphigoid induction in 24 out of 313 patients. Front Immunol. 2018;9:1030.","journal-title":"Front Immunol"},{"key":"3257_CR57","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.jdcr.2021.07.027","volume":"15","author":"CP Burruss","year":"2021","unstructured":"Burruss CP, Jones JM, Burruss JB. Semaglutide-associated bullous pemphigoid. JAAD Case Rep. 2021;15:107\u20139.","journal-title":"JAAD Case Rep"},{"key":"3257_CR58","first-page":"9676","volume":"15","author":"B Sonego","year":"2023","unstructured":"Sonego B, Zelin E, Zalaudek I, di Meo N. Bullous pemphigoid triggered by dulaglutide: a case report and a review of the literature. Dermatol Rep. 2023;15:9676.","journal-title":"Dermatol Rep"},{"key":"3257_CR59","doi-asserted-by":"publisher","first-page":"E9","DOI":"10.12788\/cutis.0262","volume":"107","author":"MK Collins","year":"2021","unstructured":"Collins MK, Choudhary S, Ho J, Bunimovich YL. Bullous pemphigoid triggered by liraglutide. Cutis. 2021;107:E9\u201311.","journal-title":"Cutis"},{"key":"3257_CR60","doi-asserted-by":"publisher","first-page":"2969","DOI":"10.1016\/j.jid.2021.05.015","volume":"141","author":"O Varpuluoma","year":"2021","unstructured":"Varpuluoma O, Jokelainen J, Huilaja L, Tasanen K. GLP-1 analogs and SGLT2 inhibitors do not increase risk of bullous pemphigoid. J Investig Dermatol. 2021;141:2969-72.e1.","journal-title":"J Investig Dermatol"},{"key":"3257_CR61","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1056\/NEJMra0804595","volume":"361","author":"FO Nestle","year":"2009","unstructured":"Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med. 2009;361:496\u2013509.","journal-title":"N Engl J Med"},{"key":"3257_CR62","doi-asserted-by":"publisher","first-page":"579","DOI":"10.3389\/fimmu.2018.00579","volume":"9","author":"WH Boehncke","year":"2018","unstructured":"Boehncke WH. Systemic inflammation and cardiovascular comorbidity in psoriasis patients: causes and consequences. Front Immunol. 2018;9:579.","journal-title":"Front Immunol"},{"key":"3257_CR63","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.605691","volume":"8","author":"V Brazzelli","year":"2021","unstructured":"Brazzelli V, Maffioli P, Bolcato V, et al. Psoriasis and diabetes, a dangerous association: evaluation of insulin resistance, lipid abnormalities, and cardiovascular risk biomarkers. Front Med (Lausanne). 2021;8:605691.","journal-title":"Front Med (Lausanne)"},{"key":"3257_CR64","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/j.jaad.2006.08.040","volume":"55","author":"AL Neimann","year":"2006","unstructured":"Neimann AL, Shin DB, Wang X, et al. Prevalence of cardiovascular risk factors in patients with psoriasis. J Am Acad Dermatol. 2006;55:829\u201335.","journal-title":"J Am Acad Dermatol"},{"key":"3257_CR65","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.diabet.2011.11.004","volume":"38","author":"M Buysschaert","year":"2012","unstructured":"Buysschaert M, Tennstedt D, Preumont V. Improvement of psoriasis during exenatide treatment in a patient with diabetes. Diabetes Metab. 2012;38:86\u20138.","journal-title":"Diabetes Metab"},{"key":"3257_CR66","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1111\/bjd.12380","volume":"169","author":"CT Reid","year":"2013","unstructured":"Reid CT, Tobin AM, Ahern T, O\u2019Shea D, Kirby B. Liraglutide in combination with acitretin for severe recalcitrant psoriasis. Br J Dermatol. 2013;169:230\u20131.","journal-title":"Br J Dermatol"},{"key":"3257_CR67","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/s00592-011-0359-9","volume":"51","author":"A Faurschou","year":"2014","unstructured":"Faurschou A, Knop FK, Thyssen JP, Zachariae C, Skov L, Vilsb\u00f8ll T. Improvement in psoriasis after treatment with the glucagon-like peptide-1 receptor agonist liraglutide. Acta Diabetol. 2014;51:147\u201350.","journal-title":"Acta Diabetol"},{"key":"3257_CR68","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1111\/exd.12081","volume":"22","author":"A Faurschou","year":"2013","unstructured":"Faurschou A, Pedersen J, Gyldenl\u00f8ve M, et al. Increased expression of glucagon-like peptide-1 receptors in psoriasis plaques. Exp Dermatol. 2013;22:150\u20132.","journal-title":"Exp Dermatol"},{"key":"3257_CR69","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1080\/09546634.2020.1826392","volume":"33","author":"L Lin","year":"2022","unstructured":"Lin L, Xu X, Yu Y, et al. Glucagon-like peptide-1 receptor agonist liraglutide therapy for psoriasis patients with type\u00a02 diabetes: a randomized-controlled trial. J Dermatol Treat. 2022;33:1428\u201334.","journal-title":"J Dermatol Treat"},{"key":"3257_CR70","doi-asserted-by":"publisher","first-page":"46","DOI":"10.3390\/biom15010046","volume":"15","author":"J Petkovi\u0107-Dabi\u0107","year":"2025","unstructured":"Petkovi\u0107-Dabi\u0107 J, Bini\u0107 I, Cari\u0107 B, et al. Effects of semaglutide treatment on psoriatic lesions in obese patients with type\u00a02 diabetes mellitus: an open-label, randomized clinical trial. Biomolecules. 2025;15:46.","journal-title":"Biomolecules"},{"key":"3257_CR71","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1080\/09546634.2021.1882658","volume":"33","author":"G Chang","year":"2022","unstructured":"Chang G, Chen B, Zhang L. Efficacy of GLP-1rA, liraglutide, in plaque psoriasis treatment with type\u00a02 diabetes: a systematic review and meta-analysis of prospective cohort and before-after studies. J Dermatol Treat. 2022;33:1299\u2013305.","journal-title":"J Dermatol Treat"},{"key":"3257_CR72","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1111\/j.1365-2133.2008.08515.x","volume":"158","author":"RG van Lingen","year":"2008","unstructured":"van Lingen RG, van de Kerkhof PC, Seyger MM, et al. CD26\/dipeptidylpeptidase\u00a0IV in psoriatic skin: upregulation and topographical changes. Br J Dermatol. 2008;158:1264\u201372.","journal-title":"Br J Dermatol"},{"key":"3257_CR73","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1111\/j.1440-0960.2011.00783.x","volume":"53","author":"A Mas-Vidal","year":"2012","unstructured":"Mas-Vidal A, Santos-Juanes J, Esteve-Martinez A, et al. Psoriasiform eruption triggered by a dipeptidyl peptidase\u00a0IV inhibitor. Australas J Dermatol. 2012;53:70\u20132.","journal-title":"Australas J Dermatol"},{"key":"3257_CR74","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1111\/exd.14228","volume":"30","author":"PM Patel","year":"2021","unstructured":"Patel PM, Jones VA, Kridin K, Amber KT. The role of dipeptidyl peptidase-4 in cutaneous disease. Exp Dermatol. 2021;30:304\u201318.","journal-title":"Exp Dermatol"},{"key":"3257_CR75","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1159\/000502130","volume":"237","author":"M Lynch","year":"2021","unstructured":"Lynch M, Malara A, Timoney I, et al. Dipeptidyl peptidase-4 inhibition in psoriasis patients with diabetes: a double-blind randomized controlled trial. Dermatology. 2021;237:66\u20139.","journal-title":"Dermatology"},{"key":"3257_CR76","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1159\/000333358","volume":"224","author":"T Nishioka","year":"2012","unstructured":"Nishioka T, Shinohara M, Tanimoto N, Kumagai C, Hashimoto K. Sitagliptin, a dipeptidyl peptidase-IV inhibitor, improves psoriasis. Dermatology. 2012;224:20\u20131.","journal-title":"Dermatology"},{"key":"3257_CR77","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1111\/ced.12408","volume":"39","author":"M Lynch","year":"2014","unstructured":"Lynch M, Tobin AM, Ahern T, O\u2019Shea D, Kirby B. Sitagliptin for severe psoriasis. Clin Exp Dermatol. 2014;39:841\u20132.","journal-title":"Clin Exp Dermatol"},{"key":"3257_CR78","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1111\/1346-8138.12955","volume":"42","author":"H Nagai","year":"2015","unstructured":"Nagai H, Fujiwara S, Takahashi Y, Nishigori C. Ameliorating effect of the novel dipeptidyl peptidase-4 inhibitor teneligliptin on psoriasis: a report of two cases. J Dermatol. 2015;42:1094\u20137.","journal-title":"J Dermatol"},{"key":"3257_CR79","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1159\/000514494","volume":"238","author":"M Lynch","year":"2022","unstructured":"Lynch M, Malara A, Timoney I, et al. Sitagliptin and narrow-band ultraviolet-B for moderate psoriasis (DINUP): a randomised controlled clinical trial. Dermatology. 2022;238:140\u20137.","journal-title":"Dermatology"},{"key":"3257_CR80","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.cpt.2024.08.002","volume":"3","author":"AH Roky","year":"2024","unstructured":"Roky AH, Islam MM, Ahasan AMF, et al. Overview of skin cancer types and prevalence rates across continents. Cancer Pathog Ther. 2024;3:89\u2013100.","journal-title":"Cancer Pathog Ther"},{"key":"3257_CR81","doi-asserted-by":"crossref","unstructured":"Nauck MA, Jensen TJ, Rosenkilde C, et al. Neoplasms reported with liraglutide or placebo in people with type\u00a02 diabetes: results from the LEADER randomized trial. Diabetes Care. 2018;41:1663\u201371.","DOI":"10.2337\/dc17-1825"},{"key":"3257_CR82","doi-asserted-by":"publisher","DOI":"10.1111\/dme.15248","volume":"41","author":"R Pradhan","year":"2024","unstructured":"Pradhan R, Yu OHY, Platt RW, Azoulay L. Glucagon like peptide-1 receptor agonists and the risk of skin cancer among patients with type\u00a02 diabetes: population-based cohort study. Diabet Med. 2024;41:e15248.","journal-title":"Diabet Med"},{"key":"3257_CR83","doi-asserted-by":"publisher","DOI":"10.1136\/bmjdrc-2023-003550","volume":"11","author":"R Pradhan","year":"2023","unstructured":"Pradhan R, Yu OHY, Platt RW, Azoulay L. Dipeptidyl peptidase-4 inhibitors and the risk of skin cancer among patients with type\u00a02 diabetes: a UK population-based cohort study. BMJ Open Diabetes Res Care. 2023;11:e003550.","journal-title":"BMJ Open Diabetes Res Care"},{"key":"3257_CR84","doi-asserted-by":"crossref","unstructured":"Barreira da Silva R, Laird ME, Yatim N, et al. Dipeptidylpeptidase 4 inhibition enhances lymphocyte trafficking, improving both naturally occurring tumor immunity and immunotherapy. Nat Immunol. 2015;16:850\u20138.","DOI":"10.1038\/ni.3201"},{"key":"3257_CR85","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1080\/13543784.2022.2113056","volume":"31","author":"Z Li","year":"2022","unstructured":"Li Z, Lin C, Zhou J, et al. Dipeptidyl peptidase 4-inhibitor treatment was associated with a reduced incidence of neoplasm in patients with type\u00a02 diabetes: a meta-analysis of 115 randomized controlled trials with 121961 participants. Expert Opin Investig Drugs. 2022;31:957\u201364.","journal-title":"Expert Opin Investig Drugs"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03257-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-025-03257-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03257-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T18:55:55Z","timestamp":1757184955000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-025-03257-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,5]]},"references-count":85,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["3257"],"URL":"https:\/\/doi.org\/10.1007\/s12325-025-03257-w","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,5]]},"assertion":[{"value":"5 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Dimitrios Pantazopoulos and Massimo Papi has no conflicts of interest. Evanthia Gouveri has attended conferences sponsored by Berlin-Chemie, Sanofi, AstraZeneca, Novo Nordisk, Lilly and Boehringer Ingelheim; received speaker honoraria by Boehringer Ingelheim and Menarini. Dimitrios Papazoglou declares associations with Menarini, Novo Nordisk, AstraZeneca, Boehringer Ingelheim and Sanofi-Aventis. Nikolaos Papanas has been an advisory board member of AstraZeneca, Bayer, Boehringer Ingelheim, Menarini, MSD, Novo Nordisk, Pfizer, Takeda and TrigoCare International; has participated in sponsored studies by AstraZeneca, Eli Lilly, GSK, MSD, Novo Nordisk, Novartis and Sanofi-Aventis; has received honoraria as a speaker for AstraZeneca, Bayer, Boehringer Ingelheim, Eli Lilly, Elpen, Menarini, MSD, Mylan, Novo Nordisk, Pfizer, Sanofi-Aventis and Vianex; and has attended conferences sponsored by TrigoCare International, Bayer, Eli Lilly, Galenica, Novo Nordisk, Pfizer and Sanofi-Aventis.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This review is based on previously conducted studies and meta-analyses and does not contain any new studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}